ANEB RSI Chart
Last 7 days
6.9%
Last 30 days
11.5%
Last 90 days
20.6%
Trailing 12 Months
33.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 71.1K | 92.4K | 0 | 0 |
2022 | 0 | 7.3K | 28.6K | 49.9K |
2021 | 0 | 1.0K | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 18, 2023 | english aron r. | gifted | - | - | -300,000 | - |
Dec 18, 2023 | english aron r. | gifted | - | - | 300,000 | - |
Nov 13, 2023 | english aron r. | acquired | - | - | 300,000 | - |
Dec 17, 2021 | english aron r. | bought | 2,634 | 6.5858 | 400 | - |
Dec 14, 2021 | english aron r. | bought | 2,428 | 5.895 | 412 | - |
Dec 03, 2021 | english aron r. | bought | 26,685 | 5.93 | 4,500 | - |
Dec 02, 2021 | english aron r. | bought | 73,330 | 5.3 | 13,836 | - |
May 06, 2021 | english aron r. | acquired | 4,999,750 | 7.00 | 714,250 | - |
May 06, 2021 | english aron r. | acquired | 5,000,000 | 7.00 | 714,286 | - |
Which funds bought or sold ANEB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 72,476 | 72,476 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 18, 2024 | LVW Advisors, LLC | reduced | -0.16 | 286,497 | 1,842,650 | 0.31% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 584 | 302,006 | 370,267 | -% |
Feb 15, 2024 | Nantahala Capital Management, LLC | added | 100 | 912,266 | 2,473,590 | 0.07% |
Feb 14, 2024 | 22NW, LP | added | 5.92 | -2,491,090 | 12,986,400 | 8.46% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 10.00 | 10.00 | -% |
Feb 14, 2024 | Praetorian PR LLC | sold off | -100 | -541,627 | - | -% |
Feb 14, 2024 | ADAR1 Capital Management, LLC | new | - | 2,945 | 2,945 | -% |
Feb 14, 2024 | Ikarian Capital, LLC | unchanged | - | -121,554 | 382,026 | 0.04% |
Peers (Alternatives to Anebulo Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.7B | 6.8B | -7.83 | 6.82 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.01 | 9.62 | ||||
BMRN | 15.5B | 2.5B | 75.6 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -9.48 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.3 | 9.79 | ||||
AXSM | 3.6B | 251.0M | -12.15 | 14.35 | ||||
ARWR | 3.1B | 240.7M | -10.53 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.28 | 4.35 | ||||
NVAX | 625.6M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 451.6M | 881.7K | -13.38 | 481.06 | ||||
INO | 257.1M | 4.9M | -1.9 | 52.83 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Anebulo Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q2 |
Revenue | 28.3% | 75,522 | 58,846 | 42,169 | 25,493 | 8,816 | - | - | - |
Operating Expenses | 8.5% | 2,760,459 | 2,543,678 | 2,494,389 | 2,864,041 | 3,813,122 | 2,612,047 | 2,325,484 | 2,484,705 |
S&GA Expenses | 33.3% | 1,697,787 | 1,273,458 | 1,077,230 | 1,774,699 | 1,943,202 | 1,388,271 | 1,207,343 | 678,013 |
R&D Expenses | -16.3% | 1,062,672 | 1,270,220 | 1,417,159 | 1,089,342 | 1,869,920 | 1,223,776 | 1,118,141 | - |
EBITDA Margin | 0% | -39.11 | -39.11 | -39.11 | -50.80 | -72.46 | -126 | -492 | - |
Interest Expenses | - | 31,838 | - | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | - | - | - | -2,552,581 |
EBT Margin | 0% | -39.11 | -39.11 | -39.11 | -50.80 | -72.46 | -126 | -492 | - |
Net Income | -9.5% | -2,717,369 | -2,480,823 | -2,495,580 | -2,797,971 | -3,826,952 | -2,611,835 | -2,322,742 | -29,111,739 |
Net Income Margin | 9.6% | -113 | -125 | -126 | -162 | -213 | -275 | -930 | - |
Free Cashflow | 33.5% | -1,813,707 | -2,726,825 | -2,849,246 | -2,190,545 | -2,609,420 | -2,033,922 | -1,999,256 | -3,497,308 |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q2 |
Assets | -17.1% | 8.00 | 9.00 | 12.00 | 14.00 | 17.00 | 20.00 | 16.00 | 17.00 | 19.00 | 21.00 | 22.00 | 4.00 | 3.00 |
Current Assets | - | 7.00 | - | 12.00 | - | - | - | - | - | - | - | - | 4.00 | 3.00 |
Cash Equivalents | -22.0% | 7.00 | 9.00 | 11.00 | 14.00 | 16.00 | 19.00 | 15.00 | 17.00 | 18.00 | 19.00 | 20.00 | 3.00 | 3.00 |
Liabilities | 41.4% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 0.00 | 11.00 | - |
Shareholder's Equity | -22.1% | 6.00 | 8.00 | 11.00 | 13.00 | 16.00 | 19.00 | 15.00 | 17.00 | 19.00 | 20.00 | 21.00 | - | - |
Retained Earnings | -4.6% | -62.40 | -59.68 | -57.20 | -54.71 | -51.91 | -48.08 | -45.47 | -43.15 | -41.27 | -40.20 | -38.64 | -9.53 | -0.18 |
Additional Paid-In Capital | 1.3% | 69.00 | 68.00 | 68.00 | 68.00 | 67.00 | 67.00 | 61.00 | 60.00 | 60.00 | 60.00 | 60.00 | 0.00 | - |
Shares Outstanding | 1.2% | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 13.00 | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 33.5% | -1,813 | -2,726 | -2,849 | -2,190 | -2,609 | -2,033 | -1,999 | -1,461 | -1,198 | -777 | -3,497 | -828 | -410 | -134 | -150 |
Share Based Compensation | 0% | 200 | 200 | 242 | 224 | 200 | 200 | 227 | 125 | 94.00 | 34.00 | 115 | 47.00 | 21.00 | 16.00 | - |
Cashflow From Financing | - | - | - | -68.16 | - | -248 | 6,699 | - | - | - | - | - | - | - | - | 3,176 |
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||||
Research and development | $ 1,062,672 | $ 1,869,920 | $ 2,332,892 | $ 3,093,696 |
General and administrative | 1,697,787 | 1,943,202 | 2,971,245 | 3,331,473 |
Total operating expenses | 2,760,459 | 3,813,122 | 5,304,137 | 6,425,169 |
Loss from operations | (2,760,459) | (3,813,122) | (5,304,137) | (6,425,169) |
Other (income) expenses: | ||||
Interest expense | 31,838 | 31,838 | ||
Interest income | (75,522) | (8,816) | (130,720) | (13,249) |
Other | 594 | 22,646 | (7,063) | 26,867 |
Other (income) expenses, net | (43,090) | 13,830 | (105,945) | 13,618 |
Net loss | $ (2,717,369) | $ (3,826,952) | $ (5,198,192) | $ (6,438,787) |
Weighted average common shares outstanding, basic | 25,789,739 | 25,633,217 | 25,711,478 | 24,524,856 |
Weighted average common shares outstanding, diluted | 25,789,739 | 25,633,217 | 25,711,478 | 24,524,856 |
Net loss per share, basic | $ (0.11) | $ (0.15) | $ (0.20) | $ (0.26) |
Net loss per share, diluted | $ (0.11) | $ (0.15) | $ (0.20) | $ (0.26) |
Condensed Balance Sheets - USD ($) | Dec. 31, 2023 | Jun. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,644,517 | $ 11,247,403 |
Prepaid expenses | 171,740 | 422,748 |
Total current assets | 6,816,257 | 11,670,151 |
Other assets: | ||
Loan commitment fees | 684,516 | |
Total assets | 7,500,773 | 11,670,151 |
Current liabilities: | ||
Accounts payable | 318,679 | 534,545 |
Accrued expenses | 694,877 | 534,256 |
Total liabilities | 1,013,556 | 1,068,801 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and June 30, 2023 | ||
Common stock, $0.001 par value; 50,000,000 and 40,000,000 shares authorized at December 31, 2023 and June 30, 2023, respectively; 25,933,217 and 25,633,217 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively | 25,934 | 25,634 |
Additional paid-in capital | 68,861,516 | 67,777,757 |
Accumulated deficit | (62,400,233) | (57,202,041) |
Total stockholders’ equity | 6,487,217 | 10,601,350 |
Total liabilities and stockholders’ equity | $ 7,500,773 | $ 11,670,151 |